- Home
- GDTC vs INTS Comparison
GDTC vs INTS Comparison
Compare GDTC & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- INTS
- Stock Information
- Founded
- GDTC 2018
- INTS 2012
- Country
- GDTC Singapore
- INTS United States
- Employees
- GDTC N/A
- INTS N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- INTS Health Care
- Exchange
- GDTC Nasdaq
- INTS Nasdaq
- Market Cap
- GDTC 28.0M
- INTS 30.8M
- IPO Year
- GDTC 2023
- INTS 2023
- Fundamental
- Price
- GDTC $2.40
- INTS $1.30
- Analyst Decision
- GDTC Buy
- INTS Strong Buy
- Analyst Count
- GDTC 1
- INTS 3
- Target Price
- GDTC $5.00
- INTS $8.50
- AVG Volume (30 Days)
- GDTC 32.5K
- INTS 37.8K
- Earning Date
- GDTC 01-01-0001
- INTS 05-08-2025
- Dividend Yield
- GDTC N/A
- INTS N/A
- EPS Growth
- GDTC N/A
- INTS N/A
- EPS
- GDTC N/A
- INTS N/A
- Revenue
- GDTC $330,254.00
- INTS N/A
- Revenue This Year
- GDTC $14.71
- INTS N/A
- Revenue Next Year
- GDTC N/A
- INTS N/A
- P/E Ratio
- GDTC N/A
- INTS N/A
- Revenue Growth
- GDTC N/A
- INTS N/A
- 52 Week Low
- GDTC $1.20
- INTS $1.27
- 52 Week High
- GDTC $4.05
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- GDTC 48.41
- INTS 22.77
- Support Level
- GDTC $2.20
- INTS $1.78
- Resistance Level
- GDTC $2.46
- INTS $1.94
- Average True Range (ATR)
- GDTC 0.21
- INTS 0.17
- MACD
- GDTC 0.01
- INTS -0.03
- Stochastic Oscillator
- GDTC 34.67
- INTS 4.10
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.